Denali Therapeutics Inc 's Income per employee fell in the second quarter 2026 on a trailing twelve month basis to $ 1,962, but the productivity of Denali Therapeutics Inc 's 503 employees remained above the company average.
The Healthcare sector has seen employees of 22 other companies achieving higher income per employee. While income per employee total ranking has improved so far to 2089, from total ranking in previous quarter at 2750.

What is Income per Employee Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Net Income per Employee▼

None ▼

Net Income per Employee▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

DNLI Net Income per Employee	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Net Income Change	-	-	24.66 %	-	-
Net Income per Employee (TTM) $	1,962	8,789	-203	-151,171	-111,986
DNLI's Total Ranking	# 2089	# 2750	# 3231	# 3173	# 3013
Seq. Net Income Change	-	-	-	-	-

DNLI Company Profile >> Back to DNLI Efficiency Comparisons >> Compare DNLI Net Income per Employee to its Competitors

DNLI Net Income per Employee Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	# 23
Healthcare Sector	# 187
Overall Market	# 2089

Net Income per Employee Statistics
High	Average	Low
$ 656,268	$ -158,026	$ -1,005,767
(Sep 30 2023)		(Dec 31 2021)

News about Denali Therapeutics Inc Income per employee

Navigating New Frontiers in Rare Disease and Neurodegeneration Denali Therapeutics’ Pivotal Milestones

Denali Therapeutics’ Recent Announcements: Key Facts and Implications Denali Therapeutics Inc., a cutting-edge biopharmaceutical company, is making significant strides in addressing complex and rare diseases through innovative therapeutic approaches. Recent press releases from the company detail two crucial developments: the extension of the FDA review timeline for the Biologics License Application (BLA) for tividenofusp alfa, a promising treatment for mucopolysaccharidosis type II (MPS II), and the initiation of a Phase 2a clinical study of the LRRK2 inhibitor BIIB122 (DNL151) for LRRK2-associated Parkinson s disease (LRRK2-PD). Key Developments: 1. FDA Review Extension for Tividenofusp Alfa: - On October 13, 2025, Denali Therapeutics announced that the FDA extended the review timeline for its BLA seeking accelerated approval of tividenofusp alfa from January 5, 2026, to April 5, 2026. This extension reflects the agency’s need for additional time to assess the data supporting the application for this treatment of Hunter syndrome, a rare lysosomal storage disorder characterized by progressive morbidity.

Companies with similar Income per Employee for 12 month ending Jun 30 2026, within Healthcare Sector	Income per Employee	Income 12 month ending Jun 30 2026	Number of Employees Jun 30 2026
Delcath Systems Inc	3,410.26	$ 0.532 Million	156
Radnet Inc	2,448.17	$ 19.272 Million	7,872
Icu Medical Inc	2,314.54	$ 30.089 Million	13,000
Addus Homecare Corp	2,078.72	$ 105.306 Million	50,659
Denali Therapeutics Inc	1,962.23	$ 0.987 Million	503
Warby Parker Inc	1,918.24	$ 7.742 Million	4,036
Lifemd Inc	1,104.82	$ 0.430 Million	389

Date modified: 2026-09-06T12:18:36+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.